Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY517717

Known as: LY 517717, LY-517717 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blood coagulation at various… Expand
Review
2013
Review
2013
After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most… Expand
  • figure 1
  • figure 2
  • table 4
Review
2013
Review
2013
Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a… Expand
Review
2012
Review
2012
Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… Expand
Review
2009
Review
2009
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… Expand
Review
2008
Review
2008
In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has… Expand
Review
2008
Review
2008
  • A. Turpie
  • European heart journal
  • 2008
  • Corpus ID: 16452979
Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Review
2007
Review
2007
  • A. Turpie
  • Arteriosclerosis, thrombosis, and vascular…
  • 2007
  • Corpus ID: 2998452
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… Expand
  • table 3
  • table 1
  • table 2
Highly Cited
2007
Highly Cited
2007
Summary.  Background: LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development.